Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediWoundMDWD +0.15%58 Net Cash per Share is $-0.07 as of Jun. 2026. GuruFocus rates MDWD with a GF Score™ of 58/100 and a GF Value™ of $10.30 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 793 Biotechnology companies, MediWound ranks worse than 87.89% on this metric.
The historical rank and industry rank for MediWound's Net Cash per Share or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Cash Ratio of MediWound was 310.40. The lowest was 4.66. And the median was 22.51.
MDWD's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 5.11 * Ranked among companies with meaningful Price-to-Net-Cash only.
MediWound (NAS:MDWD) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
MediWound Net Cash per Share Related Terms
MediWound Net Cash per Share Historical Data
* Premium members only.
The historical data trend for MediWound's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDWD vs WHWK, IMUX, IVVD: Net Cash per Share Comparison
For the Biotechnology subindustry, MediWound's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediWound Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MediWound's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where MediWound's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
MediWound's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediWound (MDWD) has a Net Cash per Share of $-0.07 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on MediWound and its competitors. Over the past decade, MediWound's Net Cash per Share has ranged from 4.66 to 310.40. According to the industry distribution chart, MediWound ranks #697 out of 793 companies in the Biotechnology industry, placing it in the top 87.9%.
Is MediWound's Net Cash per Share too high?
MediWound's current Net Cash per Share is $-0.07. Over the past 10 years, this metric has ranged from a low of 4.66 to a high of 310.40. Based on the distribution chart, MediWound ranks #697 out of 793 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MediWound has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediWound's Net Cash per Share compare to WHWK and IMUX?
According to the Biotechnology industry distribution chart, MediWound ranks #697 out of 793 companies for Net Cash per Share. This places MediWound in the lower half of its industry. The industry median Net Cash per Share is 5.11. Historically, MediWound's own Net Cash per Share has ranged from 4.66 to 310.40 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.11, based on 793 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on MediWound and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediWound's current Net Cash per Share is $-0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediWound stock overvalued right now?
Based on GuruFocus' analysis, MediWound (MDWD) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.30, compared to a current price of $13.56 — trading 31.7% above its estimated fair value. The current Net Cash per Share is $-0.07. MediWound's overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For MediWound (MDWD), the current Net Cash per Share is $-0.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediWound (MDWD) Overvalued in 2026?
Based on GuruFocus' analysis, MediWound stock appears to be overvalued.
The current stock price of $13.56 is trading 31.7% above its estimated GF Value™ of $10.30.
GuruFocus considers MediWound to be Significantly Overvalued.
Key valuation signals for MDWD:
Net Cash per Share: $-0.07
GF Value™: $10.30 vs. price of $13.56 (31.7% above fair value)
No single metric tells the full story. See the MDWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
58GF Score
Get the complete analysis for MDWD
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDWD has been successfully added to your 
